Annals of Oncology 11:367-371, 2000
© 2000 European Society for Medical Oncology
other |
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study
National Tumor Institute of Naples Naples, Italy
Correspondence to: G. Frasci, MD, Division of Medical Oncology A, National Tumor Institute, Via Mariano Semmola, 80131 Naples, Italy. E-mail: gifrasci{at}sirio-oncology.it
Purpose: The objective of this study was to determine the docetaxel MTD when combined with gemcitabine or vinorelbine in advanced breast cancer patients who had received previous anthracycline-based chemotherapy for advanced disease.
Patients and methods: Advanced breast cancer patients aged between 18 and 70 with ECOG PS 0–2 who had not responded to, or had relapsed after, first-line anthracycline-based chemotherapy, were randomized to receive either gemcitabine 1000 mg/m2 or vinorelbine 25 mg/m2 in combination with escalating doses of docetaxel (starting from 30 mg/m2), all on days 1 and 8 every three weeks. Escalation was stopped if > 33% of patients treated at a given dose level showed DLT at the first cycle.
Results: A total of 34 patients with locally advanced (8) or metastatic disease (26) were treated, for a total of 94 cycles delivered. Nineteen patients received docetaxel in combination with gemcitabine and 15 with vinorelbine. All patients had been pretreated with anthracyclines, and 24 of 34 had also received weekly dose-dense paclitaxel. A docetaxel dose of 40/m2 proved to be safe when combined on days 1 and 8 with gemcitabine, while a dose of 35 mg/m2 was tolerated in combination with vinorelbine. Overall, nine episodes of DLT, all of them neutropenia, occurred at the first cycle. Considering all 94 cyles, grades 3 or 4 neutropenia and thrombocytopenia occurred in 15 (44%), and 7 (20%) patients. Non-hematologic toxicity was mild, except for three cases of grade 2 peripheral neuropathy. All patients were assessed for response on an ‘intent-to-treat’ basis. Overall, five partial responses were recorded (docetaxel $ gemcitabine = 3 and docetaxel $ vinorelbine = 2), for a 15% (95% CI: 5%–31%) overall response rate. Only 1 of 24 (4%) patients who had received weekly dose-dense paclitaxel responded to treatment.
Conclusions: The weekly docetaxel administration in combination with either gemcitabine or vinorelbine is a well-tolerated treatment for heavily pretreated advanced breast cancer patients. This approach, although sometimes capable of achieving a major response, does not seem advisable in advanced breast cancer patients refractory to both anthracyclines and paclitaxel.
docetaxel $ gemcitabine, docetaxel $ vinorelbine, phase I, breast cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Chan, G. Romieu, J. Huober, T. Delozier, M. Tubiana-Hulin, A. Schneeweiss, A. Lluch, A. Llombart, A. du Bois, R. Kreienberg, et al. Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer J. Clin. Oncol., April 10, 2009; 27(11): 1753 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Eniu, F. M. Palmieri, and E. A. Perez Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer Oncologist, October 1, 2005; 10(9): 665 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Kornek, K. Haider, W. Kwasny, M. Raderer, B. Schull, T. Payrits, D. Depisch, E. Kovats, F. Lang, and W. Scheithauer Treatment of Advanced Breast Cancer with Docetaxel and Gemcitabine with and without Human Granulocyte Colony-stimulating Factor Clin. Cancer Res., May 1, 2002; 8(5): 1051 - 1056. [Abstract] [Full Text] [PDF]
|
|